Sep 09, 2025
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Jul 25, 2025
Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
Jul 22, 2025
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Jul 09, 2025
Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
Jun 01, 2025
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
May 22, 2025
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
Apr 23, 2025
Taiho Oncology to Share Data in Five Presentations, Including Two Oral Presentations, at the 2025 American Society of Clinical Oncology Annual Meeting
Jan 14, 2025
Taiho Oncology Announces Decitabine and Cedazuridine to be Included in NIH Precision Medicine Trials
Jan 08, 2025
Taiho Oncology to Present Data at the 2025 ASCO Gastrointestinal Cancers Symposium
Dec 09, 2024
Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers
Nov 05, 2024
Taiho Oncology to Present Data at the 66th American Society of Hematology Annual Meeting
Jul 23, 2020
NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology